Protocol summary

Study aim
This study aims to compare the efficacy of extended-release (XR) and immediate-release (IR) metformin in controlling blood glucose levels among women with gestational diabetes mellitus (GDM). Adverse effects and tolerability will also be compared.
Design
Two-arm, parallel-group, open-label randomized controlled trial designed to compare the efficacy of two metformin formulations in women with gestational diabetes mellitus. Participants will be assigned to two treatment groups using block randomization with a 1:1 allocation ratio.
Settings and conduct
The study will be conducted at Ghaem Hospital, Mashhad, Iran. Eligible women with GDM will be randomly assigned to XR or IR metformin. Fasting and postprandial glucose levels, adverse effects, and the need for insulin therapy will be assessed.
Participants/Inclusion and exclusion criteria
Women aged 18–45 years with singleton pregnancies at 24–26 weeks of gestation, diagnosed with GDM by OGTT, will be enrolled after informed consent. Exclusion criteria include interacting medications, creatinine >1.2 mg/dL, metformin hypersensitivity, heart failure, myocardial infarction, moderate to severe pulmonary disease, and adrenal or pituitary insufficiency.
Intervention groups
Participants will receive either IR or XR metformin, starting at 500 mg with dinner. Doses will be adjusted according to the study protocol based on glycemic control. Blood glucose levels and adverse effects will be monitored in both groups.
Main outcome variables
Fasting blood glucose (FBG), one-hour postprandial blood glucose, and two-hour postprandial blood glucose levels.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20130914014649N5
Registration date: 2026-11-16, 1405/08/25
Registration timing: registered_while_recruiting

Last update: 2026-11-16, 1405/08/25
Update count: 0
Registration date
2026-11-16, 1405/08/25
Registrant information
Name
Fatemeh Tara
Name of organization / entity
Omolbanin Hospital, Taghiabad Avenue
Country
Iran (Islamic Republic of)
Phone
+98 51 1841 2477
Email address
taraf@mums.ac.ir
Recruitment status
recruiting
Funding source
Expected recruitment start date
2026-11-12, 1405/08/21
Expected recruitment end date
2026-12-06, 1405/09/15
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparative Efficacy of Extended-released Versus Immediate-release Metformin on Glycemic Control in Women with Gestational Diabetes Mellitus:A Randomized Controlled Trial
Public title
Comparing the Effects of Extended-Release and Immediate-Release Metformin on Blood Sugar Control in Women with Gestational Diabetes
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Pregnant women aged 18-45 years with singleton pregnancies at 24-26 weeks of gestation Diagnosed of gestational diabetes mellitus (GDM) based on an oral glucose tolerance test (OGTT)
Exclusion criteria:
Use of medications that interact with metformin or affect blood glucose levels Serum creatinine greater than 1.2 mg/dl History of known hypersensitivity to metformin Heart failure History of myocardial infarction Moderate to severe pulmonary disease Adrenal insufficiency Pituitary insufficiency
Age
From 18 years old to 45 years old
Gender
Female
Phase
1
Groups that have been masked
No information
Sample size
Target sample size: 37
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, eligiblepatients will be randomly assigned to two groups receiving either extended-released metformin (xr) or immediate-released metformin (ir) after providing informed consent. Block randomization with a1:1 allocation ratio will be used. The random allocation sequence will be generated using the online Sealed Enveloped randomization tool with block sizes of 4 and 6.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Mashhad University of Medical Sciences
Street address
Ahmadabad Street, Ghaem Hospital, Mashhad, Iran.
City
Mashhad
Province
Razavi Khorasan
Postal code
9175835743
Approval date
2026-09-21, 1405/06/30
Ethics committee reference number
IR.MUMS.IRH.REC.1405.142

Health conditions studied

1

Description of health condition studied
Gestational Diabetes Mellitus
ICD-10 code
O24.4
ICD-10 code description
Gestational diabetes mellitus

Primary outcomes

1

Description
Fasting Blood Glucose
Timepoint
At baseline ( 24-26 weeks of gestation), during treatment follow up, and at delivery.
Method of measurement
FBS will be measured after at least 8 hours of fasting using a glucometer or laboratory blood glucose testing, expressed in mg/dl.

2

Description
One hour Postprandial Blood Glucose
Timepoint
At baseline ( 24-26 weeks of gestation), during treatment follow up, and at delivery.
Method of measurement
Blood Glucose will be measured one hour after the start of a meal, using a glucometer or laboratory blood glucose testing, expressed in mg/dl.

3

Description
Two hour Postprandial Blood Glucose
Timepoint
At baseline ( 24-26 weeks of gestation), during treatment follow up, and at delivery.
Method of measurement
Blood Glucose will be measured two hour after the start of a meal, using a glucometer or laboratory blood glucose testing, expressed in mg/dl.

Secondary outcomes

1

Description
Incidence of adverse effects associated with extended-release and immediate-release metformin.
Timepoint
From treatment initiation, during follow-up visits until delivery.
Method of measurement
Assessment and recording of patient-reported adverse effects and physician evaluations throughout treatment.

2

Description
Number and percentage of patients requiring insulin therapy due to inadequate glycemic control with metformin.
Timepoint
From metformin initiation, during follow-up visits until delivery.
Method of measurement
Review of medical records to identify patients who require initiation of insulin therapy due to inadequate glycemic control, based on the treating physician’s assessment.

Intervention groups

1

Description
Intervention group: Pregnant women diagnosed with gestational diabetes mellitus will receive extended-release metformin (XR). Treatment will be initiated at an oral dose of 500 mg once daily with dinner. The dose will be adjusted according to blood glucose levels and patient tolerability, based on the study protocol. Treatment will continue until delivery.
Category
Treatment - Drugs

2

Description
Intervention group: Pregnant women diagnosed with gestational diabetes mellitus will receive immediate-release metformin (IR). Treatment will be initiated at an oral dose of 500 mg once daily with dinner. The dose will be adjusted according to blood glucose levels and patient tolerability, based on the study protocol. Treatment will continue until delivery.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Ghaem Hospital
Full name of responsible person
Zahra Motevasselian
Street address
Ghaem Hospital, Ahmadabad Street, Mashhad, Iran.
City
Mashhad
Province
Razavi Khorasan
Postal code
9175835743
Phone
+98 936 395 8012
Email
Dinam6812@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Fatemeh Tara
Street address
mah ir 8:52 PM (0 minutes ago) to me Shahid Kaveh Boulevard, Namaz Boulevard, Mashhad, Iran.
City
Mashhad
Province
Razavi Khorasan
Postal code
9177899191
Phone
+98 51 3871 3634
Email
Dinam6812@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mashhad University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Zahra Motevasselian
Position
Resident in Obstetrics and Gynecology
Latest degree
Medical doctor
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Ahmadabad Street, Ghaem Hospital
City
Mashhad
Province
Razavi Khorasan
Postal code
9175835743
Phone
+98 51 3840 9169
Email
Dinam6812@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Fatemeh Tara
Position
Full Professor
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Umm Al-Banin Hospital, Behjat 16, Behjat Street, Mashhad, Razavi Khorasan Province, Iran.
City
Mashhad
Province
Razavi Khorasan
Postal code
9144734756
Phone
+98 51 3223 1444
Email
taraf@mums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Zahra Motevasselian
Position
Resident in Obstetrics and Gynecology
Latest degree
Medical doctor
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Ahmadabad Street, Ghaem Hospital
City
Mashhad
Province
Razavi Khorasan
Postal code
9175835743
Phone
+98 51 3840 9169
Email
Dinam6812@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...